NCT06451770View on ClinicalTrials.gov

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Hypercholesterolemia
Interventions
DRUG

VERVE-201

Intravenous (IV) infusion

Trial Locations (7)

Unknown

RECRUITING

Clinical Study Center, Melbourne

RECRUITING

Clinical Study Center, Chicoutimi

RECRUITING

Clinical Study Center, Montreal

RECRUITING

Clinical Study Center, Toronto

RECRUITING

Clinical Study Center, Johannesburg

RECRUITING

Clinical Study Center, London

RECRUITING

Clinical Study Center, Manchester

All Listed Sponsors
lead

Verve Therapeutics, Inc.

INDUSTRY